OLD Category: GeoMx DSP

May 5, 2023 / Trends Cancer

  • Ceyhan Y, Garcia NMG, Alvarez JV
Tumor recurrence following potentially curative therapy constitutes a major obstacle to achieving cures in patients with cancer. Recurrent tumors frequently arise from a population of residual cancer cells – also…
May 1, 2023 / Nat Cancer

  • Kraemer AI, Chong C, Huber F, Pak H, Stevenson BJ, Müller M, Michaux J, Altimiras ER, Rusakiewicz S, Simó-Riudalbas L, Planet E, Wiznerowicz M, Dagher J, Trono D, Coukos G, Tissot S, Bassani-Sternberg M
One key barrier to improving efficacy of personalized cancer immunotherapies that are dependent on the tumor antigenic landscape remains patient stratification. Although patients with CD3+CD8+ T cell-inflamed tumors typically show…
May 1, 2023 / Front Oncol

  • Lee RY, Ng CW, Rajapakse MP, Ang N, Yeong JPS, Lau MC
Growing evidence supports the critical role of tumour microenvironment (TME) in tumour progression, metastases, and treatment response. However, the in-situ interplay among various TME components, particularly between immune and tumour…
April 27, 2023 / Nat Commun

  • Robertson AG, Meghani K, Cooley LF, McLaughlin KA, Fall LA, Yu Y, Castro MAA, Groeneveld CS, de Reyniès A, Nazarov VI, Tsvetkov VO, Choy B, Raggi D, Marandino L, Montorsi F, Powles T, Necchi A, Meeks JJ
Checkpoint immunotherapy (CPI) has increased survival for some patients with advanced-stage bladder cancer (BCa). However, most patients do not respond. Here, we characterized the tumor and immune microenvironment in pre-…
April 27, 2023 / Cancer Res Commun

  • Bonnett SA, Alyssa B Rosenbloom, Giang T Ong, Mark Conner, Aric BE Rininger, Daniel Newhouse, Felicia New, Chi Q. Phan, Saskia Ilcisin, Hiromi Sato, John S Lyssand, Gary Geiss, Joseph M. Beechem
A deeper understanding of complex biological processes, including tumor development and immune response, requires ultra high-plex, spatial interrogation of multiple “omes”. Here we present the development and implementation of a…
April 27, 2023 / OncoImmunology

  • Gerdtsson AS, Mattis Knulst, Johan Botling, Artur Mezheyeuski, Patrick Micke, Sara Ek
The immune microenvironment of non-small cell lung cancer (NSCLC) is heterogeneous, which impedes the prediction of response to immune checkpoint inhibitors. We have mapped the expression of 49 proteins to…
April 26, 2023 / J Pathol

  • Tarullo SE, He Y, Daughters C, Knutson TP, Henzler CM, Price MA, Shanley R, Witschen P, Tolg C, Kaspar RE, Hallstrom C, Gittsovich L, Sulciner ML, Zhang X, Forster CL, Lange CA, Shats O, Desler M, Cowan KH, Yee D, Schwertfeger KL, Turley EA, McCarthy JB, Nelson AC
Breast cancer invasion and metastasis result from a complex interplay between tumor cells and the tumor microenvironment (TME). Key oncogenic changes in the TME include aberrant synthesis, processing and signaling…
April 24, 2023 / J Immunother Cancer

  • Jung J, Heo YJ, Park S
Background: Tumor mutation burden (TMB) is an important biomarker to predict response to anti-PD-L1 treatment across cancer types. TruSight Oncology 500 (TSO500) is currently used globally as a routine assay…
April 20, 2023 / Res Pract Thromb Haemost

  • Tilburg J, Andrew Stone, James Billingsley, David Scoville, Anna Pavenko, Yan Liang, Joseph Italiano, Kellie Machlus
Background: While megakaryocytes are known for making platelets, recent single cell RNA sequencing data have revealed subpopulations of megakaryocytes with predicted immunoregulatory and bone marrow niche-supporting roles. Although these studies…
April 19, 2023 / Cancer Immunol Res

  • Nirschl CJ, Brodkin HR, Domonkos C, Dwyer CJ, Hicklin DJ, Ismail N, Seidel-Dugan C, Steiner P, Steuert Z, Sullivan JM, Winston WM, Salmeron A
IL-12 is a pleotropic inflammatory cytokine that has broad stimulatory effects on various immune cell populations, making it an attractive target for cancer immunotherapy. However, despite generating robust antitumor activity…
April 18, 2023 / Mol Cancer Ther

  • Mender I, Siteni S, Barron S, Flusche AM, Kubota N, Yu C, Cornelius C, Tedone E, Maziveyi M, Grichuk A, Venkateswaran N, Conacci Sorrell M, Hoshida Y, Kang R, Tang D, Gryaznov S, Shay JW
A select group of hepatocellular carcinomas (HCC) patients benefit from surgical, radiological, and systemic therapies that include a combination of anti-angiogenic and immune-checkpoint inhibitors. However, since HCC is generally asymptomatic…
April 18, 2023 / Nat Commun

  • Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, Hillman DW, Tenner KS, Kachergus JM, Brauer HA, Warren SE, Henderson D, Shi J, Liu Y, Joensuu H, Lindman H, Leon-Ferre RA, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Knutson KL, Goetz MP, Perez EA, Thompson EA
The utility of spatial immunobiomarker quantitation in prognostication and therapeutic prediction is actively being investigated in triple-negative breast cancer (TNBC). Here, with high-plex quantitative digital spatial profiling, we map and…